Aktienanalyse zu Compass Therapeutics Inc. (CMPX)CMPXCompass Therapeutics Inc.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, Compass Therapeutics Inc. (CMPX) is not a good buy. The stock is trading at $0.7675, down 85.15% year-to-date, and has an RSI of 35.791, indicating it is oversold but not necessarily a buy signal. Furthermore, the company has reported negative net income for multiple quarters, with a loss of $25,154,000 in Q2 2026. Analysts have cut their price targets significantly, with Wedbush lowering its target from $5 to $1, indicating a potential further downside of 19% from recent prices. The primary risk is the FDA's requirement for a new trial to demonstrate survival benefits for its lead drug, which complicates its approval process and could delay potential revenue.